Results 31 to 40 of about 71,439 (210)

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer. [PDF]

, 2017
PurposeCabozantinib is a multi-kinase inhibitor that targets MET, AXL, and VEGFR2, and may synergize with EGFR inhibition in NSCLC. Cabozantinib was assessed alone or in combination with erlotinib in patients with progressive NSCLC and EGFR mutations who
Engelman, Jeffrey, Gettinger, Scott, Jänne, Pasi A, Lara, Primo N, Leach, Joseph, Miles, Dale R, Subramaniam, Deepa S, Wakelee, Heather A, Wax, Michael, West, Howard, Yaron, Yifah   +10 more
core   +2 more sources

Erlotinib-Associated Acute Pneumonitis: Report of Two Cases

Canadian Respiratory Journal, 2007
Two cases of erlotinib-associated acute pneumonitis are described. The first patient was started on erlotinib treatment for metastatic non-small cell lung cancer.
Bobbak Vahid, Ali Esmaili
doaj   +1 more source

Identification of MMP1 as a potential gene conferring erlotinib resistance in non-small cell lung cancer based on bioinformatics analyses

Hereditas, 2020
Background Non-small cell lung cancer (NSCLC) is the major type of lung cancer with high morbidity and poor prognosis. Erlotinib, an inhibitor of epidermal growth factor receptor (EGFR), has been clinically applied for NSCLC treatment.
Huyue Zhou, Qiumei Xiang, Changpeng Hu, Jing Zhang, Qian Zhang, Rong Zhang   +5 more
doaj   +1 more source

Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents [PDF]

, 2014
Hepatitis C virus (HCV) is transmitted between hepatocytes via classical cell entry but also uses direct cell-cell transfer to infect neighboring hepatocytes.
A Owsianka, A Sigal, Aleem Siddiqui, Arvind H. Patel, AS Lok, AW Tarr, B Bartolini, B Sainz Jr, C Hezode, C Lee, C Nathan, C Sarrazin, CL Brimacombe, CM Lange, CT Jones, D Masson, D Trono, EJ Gane, Eric Soulier, F Kuonen, F Poordad, F Poordad, Fei Xiao, François Habersetzer, G Koutsoudakis, H Kwon, H Yan, H Zhu, Heidi Barth, I Fofana, I Fofana, I Fofana, IA Abela, IM Jacobson, Isabel Fofana, J Grove, J Lupberger, J Witteveldt, J Zhong, Jens Bukh, JG McHutchison, JM Gottwein, JM Gottwein, JM Pawlotsky, JM Pawlotsky, JM Pawlotsky, JM Timpe, L Rong, L Zona, Laura Heydmann, LW Meredith, MB Zeisel, MB Zeisel, Michel Doffoël, Mirjam B. Zeisel, MN Zahid, MS Sulkowski, MT Catanese, N Shi, O Lenz, P Zhong, PM Trembling, Q Sattentau, S Haid, T Pietschmann, T Pietschmann, T Wakita, Thomas F. Baumert, TJ Liang, TK Scheel, V Soriano, VD Cataldo, ZY Keck   +72 more
core   +7 more sources

Erlotinib-Induced Papulopustular Eruption and Mucositis

Southern Clinics of Istanbul Eurasia, 2018
Erlotinib is an epidermal growth factor inhibitor that is used in the treatment of advanced stage cancers. Cutaneous reactions to erlotinib use have been observed. A 70-year-old male patient presented with the complaint of a rash on his nose and a lesion
Zehra Aşiran Serdar, Ezgi Aktaş Karabay   +1 more
doaj   +1 more source

Design, synthesis and biological evaluation of erlotinib-based IDO1 inhibitors

Frontiers in Pharmacology, 2022
Erlotinib is a highly specific and reversible epidermal growth factor receptor tyrosine kinase inhibitor for the targeted therapy of non-small-cell lung cancer (NSCLC) However, the efficacy of erlotinib is limited because the development of drug ...
Xi-xi Hou, Xiao-qing Gong, Long-fei Mao, Ge Sun, Ge Sun, Jian-xue Yang, Jian-xue Yang   +6 more
doaj   +1 more source

Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. [PDF]

, 2017
Casitas B-lineage lymphoma (CBL) is an E3 ubiquitin ligase and a molecule of adaptor that we have shown is important for non-small-cell lung cancer (NSCLC). We investigated if MET is a target of CBL and if enhanced in CBL-altered NSCLC.
Batra, Surinder K, Husain, Aliya N, Mirzapoiazova, Tamara, Salgia, Ravi, Sharma, Sherven, Srivastava, Minu K, Tan, Yi-Hung Carol, Vokes, Everett E, Won, Brian M, Zhu, Li   +9 more
core   +1 more source

Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study

Frontiers in Oncology, 2020
Background: Erlotinib-based combination therapy leads to increased efficacy but also toxicity for EGFR-mutated NSCLC. Reducing the dose of erlotinib could improve treatment tolerability, but few evidences are available regarding its efficacy at reduced ...
Shen Zhao, Shen Zhao, Shen Zhao, Zhen Zhang, Zhen Zhang, Zhen Zhang, Zhen Zhang, Wenfeng Fang, Wenfeng Fang, Wenfeng Fang, Yaxiong Zhang, Yaxiong Zhang, Yaxiong Zhang, Zhonghan Zhang, Zhonghan Zhang, Zhonghan Zhang, Shaodong Hong, Shaodong Hong, Shaodong Hong, Yuxiang Ma, Yuxiang Ma, Yuxiang Ma, Ting Zhou, Ting Zhou, Ting Zhou, Yunpeng Yang, Yunpeng Yang, Yunpeng Yang, Yan Huang, Yan Huang, Yan Huang, Hongyun Zhao, Hongyun Zhao, Hongyun Zhao, Li Zhang, Li Zhang, Li Zhang   +36 more
doaj   +1 more source

Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy. [PDF]

, 2018
BACKGROUND:We report the successful treatment of the patient with osimertinib 80 mg/day following disease progression and a discordance in the detection of a mechanism of resistance epithelial growth factor receptor (EGFR) T790 M between liquid biopsy ...
Mambetsariev, Isa, Salgia, Ravi, Vora, Lalit, Yu, Kim Wai   +3 more
core   +1 more source

The contribution of age structure to cell population responses to targeted therapeutics [PDF]

, 2012
Cells grown in culture act as a model system for analyzing the effects of anticancer compounds, which may affect cell behavior in a cell cycle position-dependent manner.
Ackleh, Ackleh, Ainseba, Ainseba, Alarcón, Angulo, Angulo, Arino, Banks, Bekkal Brikci, Bekkal Brikci, Bernard, Calsina, Darren R. Tyson, Diekmann, Douglas, Doumic, Doumic, Dowling, Engel, Engl, Gabriel, Gabriel, Gerlee, Glenn F. Webb, Golubev, Gyllenberg, Gyllenberg, Gyllenberg, Hinow, Kostova, Lee, Liu, Mallet, Michel, Patel, Perthame, Perthame, Picart, Picart, Pierre Gabriel, Pilant, Pilant, Powathil, Quaranta, Quaranta, Ramis-Conde, Ribba, Rundell, Rundell, Shawn P. Garbett, Vito Quaranta, Webb   +52 more
core   +7 more sources